Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURMOUNT-ADOLESCENTS-2: Tirzepatide in Adolescents with Obesity
NCT06439277Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2024
- Primary completion
- Oct 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Tirzepatide with Placebo (2 arms). Primary endpoints: Percent Change from Baseline in Body Mass Index (BMI) at 72 weeks and Composite Endpoint of Normalization or Clinically Significant Improvement in At Least 2 Predefined Weight-Related Comorbidities at 72 weeks. Started Jun 2024; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06439277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439277.